PDCI Market Access recently launched the International Trends Series, which provides the results of an online survey PDCI conducted between March 19, 2015 and March 25, 2015. Participants were stakeholders in Europe and Canada. The first issue, “Delisting of Oncology Treatments” was released last week. This current issue reveals the ... Read More
News & Events
14
May2015
04
May2015
In preparation for the recent Pharma Symposium conference held in Toronto on March 31-April 1, PDCI conducted an online survey of a select group of pharmaceutical stakeholders in Canada and Europe. The purpose of this survey was to gauge whether some of the cost containment mechanisms being implemented in certain ... Read More
10
Apr2015
PDCI Presentation at Women In Bio (Montreal Chapter) – April 16th, 2015
The Greater Montreal Chapter of Women In Bio will present a half-day conference followed by a keynote lunch on the latest developments and trends affecting market access ... Read More
10
Apr2015
Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf
Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca
For more information, please see ... Read More
07
Apr2015
CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month.
Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation.
For ... Read More
30
Mar2015
We recently participated in Mediaplanet Canada’s Rare Diseases campaign in which many industry leaders united to provide Canadians with a comprehensive view of Canada’s healthcare system and the policies that affect the lives of those living with or affected by rare disorders. The campaign was distributed through the National Post on ... Read More
25
Mar2015
Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto.
Please note the new main telephone and fax ... Read More
25
Mar2015
PDCI is now offering a FREE TRIAL of its Canadian Drug Claims Database.
For those who are interested in the database and would like to learn more, this free trial gives registrants the opportunity to explore the database and test out its functionality at no cost!
For more information and to register, please ... Read More
12
Mar2015
Category 1 requirements for products that undergo a tailored CDR review have been revised. Submissions for new combination products (funded components) and new combination products designated by CADTH to undergo a tailored CDR review will require completion of the revised New Combination Product Submission Template. This revised template ... Read More
05
Mar2015
CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More